No Data
No Data
Target Price raised by 33%! JPMorgan is bullish on Contemporary Amperex Technology: technological innovation and global market expansion drive growth.
JPMorgan believes that due to the accelerated growth in sales, potential increases in unit economic efficiency, and its position as a CSI Leading Technology Index, the core competitive advantages of Contemporary Amperex Technology are promising. The target price has been significantly raised from 300 yuan to 400 yuan, indicating a potential increase of 53.9% compared to Tuesday's closing price.
A value-added rate of 2181.35%! Nanchip Technology plans to acquire 100% equity of Shengshengwei for no more than 0.16 billion yuan, focusing on the MCU chip Business.
1. Nanchip Technology stated that this acquisition is part of a strategy to "horizontally expand the product categories," adding the MUC chip business to its existing embedded chip foundation; 2. This acquisition was assessed using the market method, with Shengshengwei's evaluation of total equity attributable to the parent company's Shareholders being 0.161 billion yuan, an increase of 0.154 billion yuan, representing a growth rate of 2181.35%.
Cailian Press Autos Morning Report [January 16]
① The Ministry of Commerce: This week, detailed implementation rules for new purchase subsidies for mobile phones and other digital products will be issued successively; ② Guangdong: The production of New energy Fund vehicles will grow by 43% in 2024, accounting for a quarter of the national total; ③ Chongqing Changan Automobile: It will enter the Europe market in 2025;
Firing the first shot for increased computing power! Driven by CPU and DCU, Haiguang Information's annual report shows net profit may increase by nearly 60%.
① Haiguang Information expects to achieve revenue of 8.72 billion to 9.53 billion yuan in 2024, a year-on-year increase of 45.04% to 58.52%; ② Regarding the reasons for performance growth, Haiguang Information stated that the rapid iteration and development of DCU products has achieved support for AI industry applications such as commercial computing.
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
Beijing Kingsoft Office Software, Inc CEO Zhang Qingyuan: Let AI become the central nervous system of every enterprise | Voices of AI Leaders ・2025
① In the past year, Beijing Kingsoft Office Software, Inc found the right direction in the field of AI: it should leverage its expertise at the application level, as future AI large models will definitely be implemented through applications; ② In the future, the goal of Beijing Kingsoft Office Software, Inc is to make AI the central nervous system of every enterprise, helping businesses establish their own 'corporate brain.'